跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

BAYER HEALTHCARE LLC

首页临床试验发起方与机构BAYER HEALTHCARE LLC

BAYER HEALTHCARE LLC

ACTIVE

3500 Paramount Pkwy, Morrisville, New Jersey, 美国www.claritin.comSubsidiary

别名:

BAYER HEALTHCARE

bayer technology and services

隶属于 BAYER AG

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

8

8 进行中

药物批准

50

批准总数

监管机构

4

监管机构数

成立时间

N/A

概览

试验阶段分布

阶段

试验数

占比

1 期

6

75.0%

试验状态分布

进行中（未招募）

8

100.0%

相关临床试验

该机构主办的试验（8）

A trial to learn how a naproxen gel affects the level of pain and soreness and how safe it is compared to both a diclofenac diethylamine gel and a placebo in participants who have an injury to muscles, ligaments, or tendons in their legs or feet

进行中（未招募）

Mar 202175 名受试者

Randomized, comparative, open label treatment with double-blind placebo-controlled periods within treatment study to evaluate the efficacy and safety of a once-a-week prophylaxis treatment with BAY 79-4980 compared to once-a-week prophylaxis treatment and to on-demand treatment with rFVIII-FS reconstituted with water for injection in previously treated patients with severe hemophilia A

进行中（未招募）

Jan 2012285 名受试者

Randomized, comparative, open label treatment with double-blind placebo-controlled periods within treatment study to evaluate the efficacy and safety of a once-a-week prophylaxis treatment with BAY 79-4980 compared to once-a-week prophylaxis treatment and to on-demand treatment with rFVIII-FS reconstituted with water for injection in previously treated patients with severe hemophilia A

进行中（未招募）

Jan 2007285 名受试者

Randomized, comparative, open label treatment with double-blind placebo-controlled periods within treatment study to evaluate the efficacy and safety of a once-a-week prophylaxis treatment with BAY 79-4980 compared to once-a-week prophylaxis treatment and to on-demand treatment with rFVIII-FS reconstituted with water for injection in previously treated patients with severe hemophilia A

进行中（未招募）

Nov 2006285 名受试者

Randomized, comparative, open label treatment with double-blind placebo-controlled periods within treatment study to evaluate the efficacy and safety of a once-a-week prophylaxis treatment with BAY 79-4980 compared to once-a-week prophylaxis treatment and to on-demand treatment with rFVIII-FS reconstituted with water for injection in previously treated patients with severe hemophilia A

进行中（未招募）

Randomized, comparative, open label treatment with double-blind placebo-controlled periods within treatment study to evaluate the efficacy and safety of a once-a-week prophylaxis treatment with BAY 79-4980 compared to once-a-week prophylaxis treatment and to on-demand treatment with rFVIII-FS reconstituted with water for injection in previously treated patients with severe hemophilia A

进行中（未招募）

Nov 2006285 名受试者

Randomized, comparative, open label treatment with double-blind placebo-controlled periods within treatment study to evaluate the efficacy and safety of a once-a-week prophylaxis treatment with BAY 79-4980 compared to once-a-week prophylaxis treatment and to on-demand treatment with rFVIII-FS reconstituted with water for injection in previously treated patients with severe hemophilia A

进行中（未招募）

Randomized, comparative, open label treatment with double-blind placebo-controlled periods within treatment study to evaluate the efficacy and safety of a once-a-week prophylaxis treatment with BAY 79-4980 compared to once-a-week prophylaxis treatment and to on-demand treatment with rFVIII-FS reconstituted with water for injection in previously treated patients with severe hemophilia A

进行中（未招募）

药物批准

按机构分类的批准

NMPA

National Medical Products Administration

7

药物批准

FDA

Food and Drug Administration

35

药物批准

CANADA

Health Canada

5

药物批准

SFDA

Saudi Food and Drug Authority

3

药物批准

近期批准

ALKA SELTZER COLD Cold Flu and Congestion Fast Dissolve

ALKA SELTZER COLD Cold and Headache Maximum Strength Fast Dissolve

ALKA SELTZER COLD Cold and Sinus Maximum Strength Day Night Fast Gels

ALKA SELTZER COLD Cold and Cough Fast

ALKA SELTZER COLD Cold Flu and Congestion Maximum Strength Day Night Fast Gels

Alka Seltzer COLD Cold Mucus Congestion Maximum Strength Fast Gels

ALKA SELTZER COLD Cold Flu and Congestion Severe Night Fast Gels

ALKA SELTZER COLD Cold and Sinus Maximum Strength Fast Gels

ALKA SELTZER COLD Cold Cough Maximum Strength Fast Gels

资讯

ISPE Celebrates 20th Anniversary with Announcement of 2025 Facility of the Year Awards Winners

- Six pharmaceutical facilities received category awards for innovation, operations, and social impact at the 2025 ISPE Europe Annual Conference, marking the 20th anniversary of the prestigious FOYA program. - Touchlight's synthetic DNA manufacturing facility and Johnson & Johnson's flexible packaging operations were among the winners recognized for advancing pharmaceutical manufacturing standards and sustainability initiatives. - The overall 2025 FOYA winner will be announced at a special black-tie celebration during the ISPE Annual Meeting & Expo in Charlotte, North Carolina in October 2025.

本页目录

概览
相关临床试验8
药物批准50
资讯1

返回机构列表